DNAprint Genomics (DNAG)

[mingwan0]

ifida, yes rings a bell.

"Of note, 18 patients treated with carboplatin were unable to move onto the next phase of the study because of hematologic toxicity, progressive disease, or other adverse events. For the same reasons, 6 patients on arm A, 10 patients on arm B, and 15 patients on arm C withdrew during the course of the randomized portion of the study. The researchers also discerned that shortness of breath was markedly increased (P = .001) in the gemcitabine arms and much more so in the weekly arm of the protocol."

Relatively high percentages of the patient populations concerned. Of course one of the projects underway in conjunciton with Moffitt is "taxanes". I wonder which ones.